Anne L Schafer

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, 4150 Clement Street, 111N, San Francisco, California 94121, USA
    J Clin Endocrinol Metab 97:3522-9. 2012
  2. ncbi Laboratory reproducibility of biochemical markers of bone turnover in clinical practice
    A L Schafer
    Department of Medicine, University of California, San Francisco, CA, USA
    Osteoporos Int 21:439-45. 2010
  3. ncbi Fat infiltration of muscle, diabetes, and clinical fracture risk in older adults
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    J Clin Endocrinol Metab 95:E368-72. 2010
  4. ncbi Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, CA 94115, USA
    J Clin Densitom 14:68-73. 2011
  5. ncbi Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study)
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    J Clin Endocrinol Metab 96:E1982-9. 2011
  6. ncbi Urine calcium excretion, cardiovascular events, and mortality in outpatients with stable coronary artery disease (from the Heart and Soul study)
    Christine C Welles
    Department of Medicine, University of California, San Francisco, California, USA
    Am J Cardiol 110:1729-34. 2012
  7. ncbi Quantification of vertebral bone marrow fat content using 3 Tesla MR spectroscopy: reproducibility, vertebral variation, and applications in osteoporosis
    Xiaojuan Li
    Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA
    J Magn Reson Imaging 33:974-9. 2011

Detail Information

Publications7

  1. ncbi Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, 4150 Clement Street, 111N, San Francisco, California 94121, USA
    J Clin Endocrinol Metab 97:3522-9. 2012
    ..PTH therapy improves bone mineral density (BMD) and decreases fractures in postmenopausal osteoporosis, but cost and the burden of daily injections limit its use...
  2. ncbi Laboratory reproducibility of biochemical markers of bone turnover in clinical practice
    A L Schafer
    Department of Medicine, University of California, San Francisco, CA, USA
    Osteoporos Int 21:439-45. 2010
    ..Longitudinal and within-run laboratory reproducibility varied substantially. Efforts to improve the reproducibility of these tests are needed...
  3. ncbi Fat infiltration of muscle, diabetes, and clinical fracture risk in older adults
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    J Clin Endocrinol Metab 95:E368-72. 2010
    ..Older adults with type 2 diabetes are at higher risk for fracture compared with nondiabetic adults after adjustment for their higher bone mineral density. Infiltration of muscle by fat predicts increased risk of hip fracture...
  4. ncbi Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, CA 94115, USA
    J Clin Densitom 14:68-73. 2011
    ..The relationship between bone turnover marker and calcium responses to PTH(1-84) is modest and does not suggest a profound, broadly heightened responsiveness of certain individuals to therapy...
  5. ncbi Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study)
    Anne L Schafer
    Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    J Clin Endocrinol Metab 96:E1982-9. 2011
    ..The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice. In human subjects, cross-sectional studies suggest a relevant association...
  6. ncbi Urine calcium excretion, cardiovascular events, and mortality in outpatients with stable coronary artery disease (from the Heart and Soul study)
    Christine C Welles
    Department of Medicine, University of California, San Francisco, California, USA
    Am J Cardiol 110:1729-34. 2012
    ..On the contrary, greater UCaE is associated with a modestly lower rate of MI. These findings suggest that greater systemic calcium absorption does not confer CV harm in outpatients with prevalent CHD...
  7. ncbi Quantification of vertebral bone marrow fat content using 3 Tesla MR spectroscopy: reproducibility, vertebral variation, and applications in osteoporosis
    Xiaojuan Li
    Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA
    J Magn Reson Imaging 33:974-9. 2011
    ....